A German family business
By the mid-20th century, inspired by Walter Evers, our team of scientists, was developing new pharmaceutical formulations using our pioneering extracts. Specialisation in medicines for common urological and gastroenterological conditions led to the launch of Eviroprostat in 1954. This effective benign prostate hyperplasia symptomatic treatment was the first of our successful portfolio of pharmaceutical formulations. Eviprostat S, Eviprostat N, Circanetten, Gallith and Harpavit followed and sealed Pharma Evers’ international reputation as experts in this field.
As business boomed, in 1922 they founded their own laboratory and the ‘Pharma Evers’ story began. The brothers developed advanced extraction processes for the active ingredients of over 50 medicinal plants, supported by Paul’s expertise in sourcing teas from around the world.
In 1933, Paul launched Pharmazeutische Fabrik Evers (Evers Pharmaceutical Factory) in Hamburg to increase manufacturing capacity. After the turmoil of the mid-20th century abated, Walter saw opportunity in combining their pharmaceutical-grade herbal extracts to achieve enhanced pharmacological effects. He took over the company and built a team of scientists and pharmacists who shared his lifelong passion.
Research & Innovation
Having specialised in the urological and gastroenterological sector, 1953 was the next major milestone in the growth of Pharma Evers. Eviprostat was successfully launched into the German market – a combination of several herbal extracts treating the symptoms of benign prostate hyperplasia.
Always science-led, Walter was instrumental in commissioning research and clinical trials to establish the safety and efficacy of each new medicine. He demanded the highest standards of his team, product quality and proven pharmacological effect – strong German values that carry-through to the present day.
In 1959 a new factory was built in Pinneberg, Germany. This boosted production and research facilities, which allowed Pharma Evers to expand distribution outside Europe.
Success in Japan
Building on the strong sales of Eviprostat in Europe, other products followed – as did export opportunities. Our story in Asia started in Japan, where Circanetten and Eviprostat were launched in 1967.
New Asian markets
Other markets were quick to recognise the health benefits of our unique German herbal pharmaceutical products and Pharma Evers now has a strong export presence in China, Hong Kong SAR, Thailand and Vietnam.
Pharma Evers’ long heritage, strong German values and success in Asian markets made the acquisition by Bright Future Group in 2018 a natural evolution. Today, we work in partnership for a brighter life, better future.
With access to the research, marketing and manufacturing capability of a supportive, significant partner, Pharma Evers’ scientists are free to leverage their decades of experience in natural herbal extracts and follow fresh lines of enquiry with a long-term outlook. Together, we use our expertise to formulate and manufacture new herbal products to benefit the health of our customers all over the world.